On the other hand, Lupin, too, rose 2 per cent to Rs 978.75 on the NSE after the company on Wednesday said it has received nod from the US health regulator to market its Atovaquone oral suspension used for prevention and treatment of a type of pneumonia.
The company has received approval to market generic Atovaquone oral suspension USP in the strength of 750 mg/5 mL from the United States Food and Drug Administration (USFDA), Lupin said in a BSE filing.
At 10:05 am, all the stocks in the Nifty Pharma index were trading higher in the range of 1 per cent to 4 per cent.